Tofacitinib, also marketed as Xeljanz, can be used as an off-label treatment of male and female pattern hair loss. Currently, Tofacintinib is only FDA approved for the treatment of rheumatoid arthritis and is in clinical trials for its effectiveness in hair loss treatment.
- avg. recovery
About the Procedure
Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are enzymes that work within the immune system and other cells to transmit signals that influence basic cell functions. By inhibiting JAKs in immune cells, Xeljanz can interfere with the immune processes which attack hair follicles causing hair loss. This pill seeks to reverse hair loss caused by alopecia areata which is a common autoimmune skin disease, causing hair loss on the scalp, face and sometimes on other areas of the body. Tofacitinib and similar medications like dutasteride are not primarily used for treatment of hair loss but have shown to decrease hair minimization. Tofacitinib is available in 5 mg tablets and the recommended dose is 5 mg twice daily. Take the medication as directed by the provider and do not increase intake if a dose is missed.
The goal of tofacitinib is to reverse hair loss created by alopecia areata.
What to Expect
Tofacitinib, also marketed as Xeljanz, can be used as an off-label treatment of male and female pattern hair loss. Here is a quick guide for what to expect before, during, and after hair loss treatment with Tofacitinib.
No special measures need to be taken before treatment.
Tofacitinib is available in 5 mg tablets with the typical dosage being 5 mg twice daily. Take medication as prescribed.
No recovery is needed from tofacitinib. Tofacitinib is a pill and unlike other forms of hair restoration such as PRP injections, normal activities can be resumed immediately.
The ideal candidate for tofacitinib is suffering from hair loss caused by alopecia areata.
Not Recommended For
Tofacintinib is currently not an FDA approved treatment for hair loss.
Side effects of tofacitinib may include increased risk of infection with serious infections occurring in approximately 2 % of patients, long term risk for cancer, reduced heart rate by approximately 5 beats per minutes, making patients with heart problems unsuitable candidates for the drug. Frequent blood monitoring is needed while on tofacitinib as the drug can irritate the liver, sometimes lower blood counts and sometimes raise cholesterol levels.